Paper41335396
Decoding the role of mesothelin in tumor dynamics and targeted treatment innovations.
Silvestri R and 4 others. Mol Biomed, 2025. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Decoding the role of mesothelin in tumor dynamics and targeted treatment innovations. Papers, record 41335396. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41335396
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| GPI-Linked Proteins | Major topic |
| Neoplasms | Major topic |
| Humans | |
| Mesothelin | |
| Tumor Microenvironment | |
| Animals | |
| Epithelial-Mesenchymal Transition | |
| Molecular Targeted Therapy | |
| Cancer-Associated Fibroblasts |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Department of Excellence 2023-2027 initiative | Ministero dell'Università e della Ricerca | PubMed |
Source PubMed
References176
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19201924 | Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. | Am J Respir Crit Care Med | 2009 | https://conductscience.org/library/papers/19201924 | PubMed |
| 2 | 40010770 | Targeting mesothelin-CD24 axis repolarizes tumor-associated macrophages to potentiate PD-1 blockade therapy in high-grade serous ovarian cancer. | J Immunother Cancer | 2025 | https://conductscience.org/library/papers/40010770 | PubMed |
| 3 | 26733616 | HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients. | Clin Cancer Res | 2016 | https://conductscience.org/library/papers/26733616 | PubMed |
| 4 | 31126960 | Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study). | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/31126960 | PubMed |
| 5 | 28507279 | Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis. | Oncotarget | 2017 | https://conductscience.org/library/papers/28507279 | PubMed |
| 6 | 40315330 | Robust differentiation of NK cells from MSLN.CAR-IL-15-engineered human iPSCs with enhanced antitumor efficacy against solid tumors. | Sci Adv | 2025 | https://conductscience.org/library/papers/40315330 | PubMed |
| 7 | 30254313 | Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin - a case-control comparison nested into a prospective cohort of asbestos-exposed workers. | Sci Rep | 2018 | https://conductscience.org/library/papers/30254313 | PubMed |
| 8 | 37501016 | Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results. | Nat Med | 2023 | https://conductscience.org/library/papers/37501016 | PubMed |
| 9 | 25613900 | Proteomics. Tissue-based map of the human proteome. | Science | 2015 | https://conductscience.org/library/papers/25613900 | PubMed |
| 10 | 32611684 | Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models. | Sci Transl Med | 2020 | https://conductscience.org/library/papers/32611684 | PubMed |
| 11 | 17909009 | High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor dependent MCAT motif. | Cancer Res | 2007 | https://conductscience.org/library/papers/17909009 | PubMed |
| 12 | 23989979 | A tumorigenic factor interactome connected through tumor suppressor microRNA-198 in human pancreatic cancer. | Clin Cancer Res | 2013 | https://conductscience.org/library/papers/23989979 | PubMed |
| 13 | 29554494 | Driving CARs on the uneven road of antigen heterogeneity in solid tumors. | Curr Opin Immunol | 2018 | https://conductscience.org/library/papers/29554494 | PubMed |
| 14 | 29507805 | Serum mesothelin and other biomarkers: what have we learned in the last decade? | J Thorac Dis | 2018 | https://conductscience.org/library/papers/29507805 | PubMed |
| 15 | 9935157 | 111Indium-labeled monoclonal antibody K1: biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin. | Int J Cancer | 1999 | https://conductscience.org/library/papers/9935157 | PubMed |
| 16 | 36564099 | Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study. | Int J Gynecol Cancer | 2023 | https://conductscience.org/library/papers/36564099 | PubMed |
| 17 | 37304291 | Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures. | Front Immunol | 2023 | https://conductscience.org/library/papers/37304291 | PubMed |
| 18 | 33476708 | Furin is not required for processing of mesothelin precursor protein. | Biochim Biophys Acta Mol Cell Res | 2021 | https://conductscience.org/library/papers/33476708 | PubMed |
| 19 | 32616712 | Histoepigenetic analysis of the mesothelin network within pancreatic ductal adenocarcinoma cells reveals regulation of retinoic acid receptor gamma and AKT by mesothelin. | Oncogenesis | 2020 | https://conductscience.org/library/papers/32616712 | PubMed |
| 20 | 26823490 | Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer. | Mol Cancer Ther | 2016 | https://conductscience.org/library/papers/26823490 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42798783 | Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42798783 | PubMed |
| 42149255 | Peptides as integrative modulators for clinical prognosis and targeted therapy in pancreatic cancer. | Discov Oncol | 2026 | https://conductscience.org/library/papers/42149255 | PubMed |
| 41994562 | Mesothelin biology and the evolving landscape of targeted immunotherapy. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/41994562 | PubMed |
| 41665753 | Obstacles and improvement strategies for CAR-T cell therapy in solid tumors. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41665753 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| MMP7 | 4316 | PubTator's text mining | https://conductscience.org/library/genes/4316 | NCBI Gene |
| MSLN | 10232 | PubTator's text mining | https://conductscience.org/library/genes/10232 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41335396
GET https://conductscience.org/api/papers/v1/41335396/references?page=2